<DOC>
	<DOCNO>NCT00005804</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage cancer cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy bone marrow transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness bone marrow transplantation treat patient hematologic cancer .</brief_summary>
	<brief_title>Bone Marrow Transplantation Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare incidence graft-versus-host disease ( GVHD ) grade III IV patient hematologic malignancy treat bone marrow transplantation ( BMT ) use donor 1 HLA-A B non-cross-reactive group mismatch v control patient previously treat BMT use donor 1 HLA-A B cross-reactive group ( CREG ) mismatch . - Compare incidence GVHD grade III IV patient hematologic malignancy treat BMT use donor 1 HLA-A B CREG mismatch v control patient previously treat BMT use matched donor . - Determine relevance HLA-DRB1 DQB1 allele mismatch BMT use donor match HLA-A , B , C. OUTLINE : Beginning least 3 week completion cytoreductive combination chemotherapy , patient age 18 undergo total body irradiation ( TBI ) twice day day -7 -4 . Patients age 18 undergo TBI twice day day -6 -4 . All patient receive cyclophosphamide IV daily day -3 -2 . Males acute lymphocytic leukemia , high-grade lymphoma , intermediate-grade lymphoma , marrow CNS involvement receive radiotherapy boost testis . On day 0 , patient receive infusion bone marrow unrelated donor 1 follow : 1 HLA-A B non-cross-reactive group mismatch ; 1 HLA-A B cross-reactive group mismatch ; HLA-A , B , C match HLA-DRB1 DQB1 mismatch . Patients follow every 6 month 2 year annually thereafter . PROJECTED ACCRUAL : A total 150 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove hematologic malignancy 1 follow type : Chronic myelogenous leukemia ( CML ) chronic , accelerate , blast* phase Acute leukemia highrisk feature diagnosis : Philadelphia chromosomepositive acute lymphocytic leukemia** Acute myeloid leukemia highrisk cytogenetics inv ( 3 ) , ( 3 ; 3 ) del ( 5q ) , 5 , del ( 7q ) , 7 , +8 , +11 , abnormal 12p , del ( 20q ) , 20 , complex abnormalities** Acute leukemia failure one course induction chemotherapy Acute leukemia first relapse* second remission Highrisk lymphoblastic lymphoma first remission NonHodgkin 's lymphoma , Hodgkin 's disease , malignant lymphoproliferative disease first remission , autologous transplantation indicate Myelodysplastic myeloproliferative syndrome ineligible Protocol FHCRC179 NOTE : * For patient acute leukemia relapse CML blast crisis , search unrelated donor begin : High probability patient 's medical condition remain stable 3 6month period need find donorAn attempt remission induction undertaken Referring physician patient accept possibility search donor cancel patient 's condition worsen NOTE : ** For newly diagnose patient highrisk acute leukemia , early referral encourage unrelated donor search may begin immediately Availability unrelated donor : 1 HLAA B noncrossreactive group ( nonCREG ) mismatch ( except CML chronic phase myelodysplastic syndrome ) OR 1 HLAA B CREG mismatch OR An HLAA , B , C match HLADRB1 DQB1 mismatch ( double mismatch ) 1 2 donor type unavailable No 1 HLAA , B , C mismatch No availability HLAidentical sibling haploidentical relative incompatible 0 1 HLAA B locus nonshared haplotype For patient diagnosis CML chronic phase , 1 HLADR locusincompatible related donor priority HLA compatible class IA B CREG locus antigenincompatible unrelated donor No severe aplastic anemia No leukoencephalopathy PATIENT CHARACTERISTICS : Age : Under 51 Eligible transplantation age 52 donor identify prior patient 's 51st birthday Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : No severe hepatic disease , include acute hepatitis Renal : Creatinine le 2 time normal Cardiovascular : No cardiac insufficiency require treatment No symptomatic coronary artery disease Pulmonary : No severe hypoxemia ( i.e. , PO2 le 70 mm Hg ) decrease DLCO ( i.e. , DLCO le 70 % predict ) OR No mild hypoxemia ( i.e. , PO2 le 80 mm Hg ) severely decrease DLCO ( i.e. , DLCO le 60 % predict ) No pulmonary fibrosis Other : No nonmalignant disease would severely limit life expectancy HIV negative No contraindication total body irradiation ( TBI ) Patients exclude study contraindication TBI may treat protocol FHCRC739 PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy great 3,000 cGy whole brain At least 6 month since prior involvedfield radiotherapy great 1,500 cGy chest abdomen Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>Burkitt lymphoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage II childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>progressive hairy cell leukemia , initial treatment</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>